Scienture Holdings Inc

Scienture Holdings secures $11 M non‑dilutive debt and a third liquid losartan patent, fueling product roll‑out, R&D, and shareholder value in healthcare tech.

Scienture Holdings secures exclusive patent for FDA‑approved highest‑dose naloxone nasal spray, positioning its digital pharmacy platform to capture a life‑saving, high‑growth opioid overdose market.

Scienture Holdings Inc. faces market turbulence after announcing a $3.9 million stock offering, despite making progress in commercializing its novel specialty products.

Scienture Holdings Inc is a pioneering force in health services IT, poised to transform the retail pharmacy experience with its innovative solutions and promising product pipeline.